ストックスクリーナーアプリを入手
232.68
3.63%
8.15
アフターアワーズ：
232.60
-0.08
-0.03%
前日終値:
$224.53
開ける：
$224.74
24時間の取引高:
859.92K
Relative Volume:
0.48
時価総額：
$31.13B
収益：
$4.29B
当期純損益:
$577.22M
株価収益率:
55.29
EPS:
4.2086
ネットキャッシュフロー:
$641.34M
1週間 パフォーマンス:
+5.90%
1か月 パフォーマンス:
-9.81%
6か月 パフォーマンス:
-27.58%
1年 パフォーマンス:
-49.08%
1日の値動き範囲:
$222.71
$232.94
1週間の範囲:
$215.46
$232.94
52週間の値動き範囲:
$197.81
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
名前
Alnylam Pharmaceuticals Inc
セクター
電話
(617) 551-8200
住所
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, MRNA, REGN, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
232.68 | 34.25B | 4.29B | 577.22M | 641.34M | 4.2086 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-16 | ダウングレード | Jefferies | Buy → Hold |
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2026-01-07 | 再開されました | Oppenheimer | Outperform |
| 2025-08-04 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-08-04 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | 再開されました | Raymond James | Outperform |
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-03-31 | 開始されました | Redburn Atlantic | Buy |
| 2025-03-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-11-12 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-08-16 | アップグレード | Goldman | Neutral → Buy |
| 2024-02-16 | ダウングレード | Goldman | Buy → Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-12-08 | 開始されました | Wells Fargo | Equal Weight |
| 2023-10-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-09-29 | 開始されました | Raymond James | Outperform |
| 2023-05-05 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | 開始されました | SMBC Nikko | Neutral |
| 2023-03-21 | 開始されました | Bernstein | Outperform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Buy |
| 2022-09-09 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-06-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-06-07 | 開始されました | William Blair | Outperform |
| 2022-04-25 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | 開始されました | Citigroup | Buy |
| 2022-02-03 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-01-03 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | アップグレード | Goldman | Neutral → Buy |
| 2021-11-22 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-10-04 | アップグレード | UBS | Neutral → Buy |
| 2021-08-04 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-02-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-02-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-01-25 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | 再開されました | Berenberg | Hold |
| 2020-09-08 | 開始されました | Citigroup | Buy |
| 2020-08-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-04-24 | 再開されました | Evercore ISI | Outperform |
| 2020-03-19 | 開始されました | Berenberg | Buy |
| 2019-12-19 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-11-20 | 開始されました | Oppenheimer | Outperform |
| 2019-11-13 | 開始されました | BofA/Merrill | Buy |
| 2019-05-23 | 再開されました | Goldman | Neutral |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-03-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2019-03-05 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | 開始されました | UBS | Neutral |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-08-13 | 繰り返されました | Stifel | Buy |
| 2018-08-07 | アップグレード | Stifel | Hold → Buy |
| 2018-05-04 | 繰り返されました | Stifel | Hold |
| 2018-03-28 | 開始されました | Evercore ISI | In-line |
すべてを表示
Alnylam Pharmaceuticals Inc (ALNY) 最新ニュース
Here's How Much $100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today - Benzinga
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), AxoGen (AXGN) and Biohaven Ltd. (BHVN) - theglobeandmail.com
ALNY Maintains by JP Morgan -- Price Target Lowered to $369 - GuruFocus
Alnylam Pharmaceuticals, Carvana, MongoDB - TradingView
Cantor Fitzgerald reiterates Neutral rating on Alnylam stock By Investing.com - Investing.com Canada
AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM - itemonline.com
Down 35% This Year, Alnylam Still Has Wall Street Calling 44% Upside - nai500.com
Alnylam Pharmaceuticals: More Than Meets The Eye After CARDIO-TTRansform (NASDAQ:ALNY) - Seeking Alpha
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation - Yahoo Finance
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. - Yahoo Finance
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. - The Motley Fool
Form 4 Alnylam Pharmaceuticals Inc For: 27 September - Investing.com India
Form 4 Alnylam Pharmaceuticals Inc For: 27 September By Investing.com - Investing.com Australia
Bernstein Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $376 - Moomoo
Alnylam Needs Stronger AMVUTTRA Execution To Justify More Upside (NASDAQ:ALNY) - Seeking Alpha
Cambridge biotech co-founded by Alnylam founder Maraganore files for IPO - The Business Journals
Endpoints 11: Forget Alnylam or The Medicines Company. Corsera is Maraganore and Meanwell’s biggest bet - Endpoints News
The next Alnylam? RNAi biotech City Therapeutics files for IPO - Endpoints News
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Price Today: $246.55 - Pluang
Alnylam Pharmaceuticals (ALNY) Short Interest & Short Float | Updated Sep 2026 $ALNY - MarketBeat
Alnylam Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Greenstreet Yvonne - moomoo.com
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Alnylam Pharmaceuticals (ALNY) Misses Q2 Earnings and Revenue Estimates - Eastern Progress
ALNY Reiterated by HC Wainwright & Co. -- Price Target Maintained at $455 - GuruFocus
H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $455 - moomoo.com
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: A Biotech Leader with a 55% Upside Potential - DirectorsTalk Interviews
Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook - Yahoo Finance
Will RNAi Market Growth Change Alnylam Stock's Narrative? - simplywall.st
Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial - TradingView
Needham Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $357 - Moomoo
Alnylam Pharmaceuticals, Inc. RNAi Roundtable Call Transcript - gurufocus.com
Alnylam Pharmaceuticals (ALNY) Highlighted As An Oligonucleotide Therapeutics Leader Through 2035 - Simply Wall Street
Is Alnylam (ALNY) Quietly Repricing Its RNAi Risk Profile Amid Oligonucleotide Market Optimism? - finance.yahoo.com
Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture - finance.yahoo.com
Alnylam Pharmaceuticals Inc (WBO:ALNY) Competitors 2026 - gurufocus.com
Alnylam Pharmaceuticals, Inc. at Morgan Stanley Global Healthcare Conference Transcript - gurufocus.com
Alnylam Pharmaceuticals (ALNY) Stock Analysis: A 49% Potential Upside Amidst Biotech Innovations - DirectorsTalk Interviews
Alnylam Pharmaceuticals (ALNY) Gains Attention After Fresh RNAi Data, Is It 33% Undervalued? - simplywall.st
If You Invested $100 In Alnylam Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today - Benzinga
Diluted earnings per share (diluted EPS) of Alnylam Pharmaceuticals, Inc – VIE:ALNY - TradingView
ETFs Investing in Alnylam Pharmaceuticals, Inc Stocks - TradingView
Why Alnylam Pharmaceuticals (ALNY) Stock Is Down Today - quiverquant.com
Best Biotech Stocks To Add to Your WatchlistSeptember 10th - MarketBeat
Here’s Why Alnylam Pharmaceuticals (ALNY) Declined - Yahoo Finance
Understanding the Setup: (ALNY) and Scalable Risk - Stock Traders Daily
ALNY Maintained by Jefferies -- Price Target Raised to $260 - GuruFocus
Alnylam at Wells Fargo conference: TTR growth stays on track By Investing.com - Investing.com South Africa
Alnylam at Wells Fargo conference: TTR growth stays on track - Investing.com
Alnylam Pharmaceuticals, Inc. at Wells Fargo Healthcare Conference Transcript - GuruFocus
Onpattro Market Analysis Reveals Trends in Changing Industry Demand - openPR.com
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: A 39% Upside Potential Amid Robust Revenue Growth - DirectorsTalk Interviews
Alnylam Pharmaceuticals Inc (ALNY) 財務データ
収益
当期純利益
現金流量
EPS
3.60%
大文字化:
|
ボリューム (24 時間):